Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: Correlation with anatomic site, pathologic variables, and clinical outcome

Journal of Clinical Oncology

Volumn 24, Issue 7, 2006, Pages 1152-1160

  Jarnagin, William R ^a   Klimstra, David S ^a   Hezel, Michael ^a   Gonen, Mithat ^a   Fong, Yuman ^a   Roggin, Kevin ^a   Cymes, Karina ^a   Dematteo, Ronald P ^a   D'Angelica, Michael ^a   Blumgart, Leslie H ^a   Singh, Bhuvanesh ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; KI 67 ANTIGEN; PROTEIN MDM2; PROTEIN P21; PROTEIN P27; PROTEIN P53; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; P27 ANTIGEN; PROTEIN BCL 2; TUMOR MARKER;

ADENOCARCINOMA; ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PAPILLOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; AGED; BILE DUCT TUMOR; CHEMISTRY; FEMALE; GALLBLADDER TUMOR; GENE EXPRESSION REGULATION; INTRAHEPATIC BILE DUCT; MALE; MIDDLE AGED; PATHOLOGY; SURVIVAL; TUMOR RECURRENCE; UPREGULATION;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL CYCLE PROTEINS; CHOLANGIOCARCINOMA; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 33644972080     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.6631     Document Type: Article

References (40)

1. Fong Y, Blumgart LH, Lin E, et al: Outcome of treatment for distal bile duct cancer. Br J Surg 83:1712-1715, 1996
2. Jarnagin WR, Ruo L, Little SA, et al: Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: Implications for adjuvant therapeutic strategies. Cancer 98:1689-1700, 2003
3. Lazaridis KN, Gores GJ: Cholangiocarcinoma, Gastroenterology 128:1655-1667, 2005
4. Weber SM, Jarnagin WR, Klimstra D, et al: Intrahepatic cholangiocarcinoma: Resectability, recurrence pattern, and outcomes. J Am Coll Surg 193:384-391, 2001
5. Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33:1353-1357, 2001
6. MacFaul GR, Chapman RW: Sclerosing cholangitis. Curr Opin Gastroenterol 21:348-353, 2005
7. Shaib Y, El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis 24:115-125, 2004
8. Chen DW, Tung-Ping PR, Liu CL, et al: Immediate and long-term outcomes of hepatectomy for hepatolithiasis. Surgery 135:386-393, 2004
9. Rashid A: Cellular and molecular biology of biliary tract cancers. Surg Oncol Clin N Am 11:995-1009, 2002
10. Yang B, House MG, Guo M, et al: Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol 18:412-420, 2005
11. Kang YK, Kim WH, Lee HW, et al: Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest 79:477-483, 1999
12. Rullier A, Le BB, Fawaz R, et al: Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol 24:870-876, 2000
13. Sherr CJ: Cancer cell cycles. Science 274:1672-1677, 1996
14. Momand J, Zambetti GP, Olson DC, et al: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245, 1992
15. Ito Y, Takeda T, Sasaki Y, et al: Expression and clinical significance of the G1-S modulators in intrahepatic cholangiocellular carcinoma. Oncology 60:242-251, 2001
16. Polyak K, Lee MH, Erdjument-Bromage H, et al: Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66, 1994
17. Katayose Y, Kim M, Rakkar AN, et al: Promoting apoptosis: A novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 57:5441-5445, 1997
18. Horie S, Endo K, Kawasaki H, et al: Overexpression of MDM2 protein in intrahepatic cholangiocarcinoma: Relationship with p53 overexpression, Ki-67 labeling, and clinicopathological features. Virchows Arch 437:25-30, 2000
19. Furubo S, Harada K, Shimonishi T, et al: Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology 35:230-240, 1999
20. Della Torre G, Pasquini G, Pilotti S, et al: TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas. Diagn Mol Pathol 9:41-46, 2000
21. Filipits M, Puhalla H, Wrba F: Low p27Kip1 expression is an independent prognostic factor in gallbladder carcinoma. Anticancer Res 23:675-679, 2003
22. Taguchi K, Aishima S, Asayama Y, et al: The role of p27kip1 protein expression on the biological behavior of intrahepatic cholangiocarcinoma. Hepatology 33:1118-1123, 2001
23. Tenjo T, Toyoda M, Okuda J, et al: Prognostic significance of p27(kip1) protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas. Oncology 58:45-51, 2000
24. Fiorentino M, Altimari A, D'Errico A, et al: Low p27 expression is an independent predictor of survival for patients with either hilar or peripheral intrahepatic cholangiocarcinoma. Clin Cancer Res 7:3994-3999, 2001
25. Ito Y, Takeda T, Sasaki Y, et al: Bcl-2 expression in cholangiocellular carcinoma is inversely correlated with biologically aggressive phenotypes. Oncology 59:63-67, 2000
26. Fong Y, Jarnagin W, Blumgart LH: Gallbladder cancer: Comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg 232:557-569, 2000
27. Jarnagin WR, Bowne W, Klimstra DS, et al: Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg 241:703-712, 2005
28. Wreesmann VB, Sieczka EM, Socci ND, et al: Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64:3780-3789, 2004
29. Wiksten JP, Lundin J, Nordling S, et al: The prognostic value of p27 in gastric cancer. Oncology 63:180-184, 2002
30. McShane LM, Radmacher MD, Freidlin B, et al: Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data. Bioinformatics 18:1462-1469, 2002
31. Rayburn E, Zhang R, He J, et al: MDM2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 5:27-41, 2005
32. Ishikawa A, Sasaki M, Sato Y, et al: Frequent p16ink4a inactivation is an early and frequent event of intraductal papillary neoplasm of the liver arising in hepatolithiasis. Hum Pathol 35:1505-1514, 2004
33. Shimonishi T, Zen Y, Chen TC, et al: Increasing expression of gastrointestinal phenotypes and p53 along with histologic progression of intraductal papillary neoplasia of the liver. Hum Pathol 33:503-511, 2002
34. Abraham SC, Lee JH, Hruban RH, et al: Molecular and immunohistochemical analysis of intraductal papillary neoplasms of the biliary tract. Hum Pathol 34:902-910, 2003
35. Leach FS, Tokino T, Meltzer P, et al: p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53:2231-2234, 1993
36. Monnand J, Jung D, Wilczynski S, et al: The MDM2 gene amplification database. Nucleic Acids Res 26:3453-3459, 1998
37. Kubbutat MH, Jones SN, Vousden KH: Regulation of p53 stability by Mdm2. Nature 387:299-303, 1997
38. Pinkas J, Naber SP, Butel JS, et al: Expression of MDM2 during mammary tumorigenesis. Int J Cancer 81:292-298, 1999
39. Bartel F, Taubert H, Harris LC: Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2:9-15, 2002
40. Zhang Z, Zhang R: p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets 5:9-20, 2005